Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The utility of HepaRG cells for bioenergetic investigation and detection of drug-induced mitochondrial toxicity.

Kamalian L, Douglas O, Jolly C, Snoeys J, Simic D, Monshouwer M, Williams DP, Kevin Park B, Chadwick AE.

Toxicol In Vitro. 2018 Aug 7. pii: S0887-2333(18)30421-1. doi: 10.1016/j.tiv.2018.08.001. [Epub ahead of print]

PMID:
30096366
2.

Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and PBPK Modeling Approaches.

Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, Matsson P, Sharma P, Snoeys J, Sugiyama Y, Tatosian D, Unadkat JD, Huang SM, Galetin A; International Transporter Consortium.

Clin Pharmacol Ther. 2018 Jul 30. doi: 10.1002/cpt.1183. [Epub ahead of print]

PMID:
30059145
3.

A drug-drug interaction study of ibrutinib with moderate/strong CYP3A inhibitors in patients with B-cell malignancies.

de Jong J, Hellemans P, De Wilde S, Patricia D, Masterson T, Manikhas G, Myasnikov A, Osmanov D, Córdoba R, Panizo C, de Zwart L, Snoeys J, Chauhan V, Jiao J, Sukbuntherng J, Ouellet D.

Leuk Lymphoma. 2018 May 30:1-8. doi: 10.1080/10428194.2018.1460474. [Epub ahead of print]

PMID:
29846137
4.

Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.

Kunze A, Ediage EN, Dillen L, Monshouwer M, Snoeys J.

Clin Pharmacokinet. 2018 Apr 16. doi: 10.1007/s40262-018-0648-3. [Epub ahead of print]

PMID:
29663259
5.

MRP2 Inhibition by HIV Protease Inhibitors in Rat and Human Hepatocytes: A Quantitative Confocal Microscopy Study.

Holmstock N, Oorts M, Snoeys J, Annaert P.

Drug Metab Dispos. 2018 May;46(5):697-703. doi: 10.1124/dmd.117.079467. Epub 2018 Mar 9.

PMID:
29523599
6.

Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study.

Bell CC, Dankers ACA, Lauschke VM, Sison-Young R, Jenkins R, Rowe C, Goldring CE, Park K, Regan SL, Walker T, Schofield C, Baze A, Foster AJ, Williams DP, van de Ven AWM, Jacobs F, Houdt JV, Lähteenmäki T, Snoeys J, Juhila S, Richert L, Ingelman-Sundberg M.

Toxicol Sci. 2018 Apr 1;162(2):655-666. doi: 10.1093/toxsci/kfx289.

7.

Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.

Njumbe Ediage E, Dillen L, Vroman A, Diels L, Kunze A, Snoeys J, Verhaeghe T.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 15;1073:80-89. doi: 10.1016/j.jchromb.2017.12.008. Epub 2017 Dec 6.

PMID:
29241088
8.

Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.

Weaver RJ, Betts C, Blomme EAG, Gerets HHJ, Gjervig Jensen K, Hewitt PG, Juhila S, Labbe G, Liguori MJ, Mesens N, Ogese MO, Persson M, Snoeys J, Stevens JL, Walker T, Park BK.

Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):767-782. doi: 10.1080/17425255.2017.1341489. Epub 2017 Jun 28. Review.

PMID:
28604124
9.

Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.

Otieno MA, Snoeys J, Lam W, Ghosh A, Player MR, Pocai A, Salter R, Simic D, Skaggs H, Singh B, Lim HK.

Toxicol Sci. 2018 Jun 1;163(2):374-384. doi: 10.1093/toxsci/kfx040.

PMID:
28206647
10.

In vitro Phase I- and Phase II-Drug Metabolism in The Liver of Juvenile and Adult Göttingen Minipigs.

Van Peer E, Jacobs F, Snoeys J, Van Houdt J, Pijpers I, Casteleyn C, Van Ginneken C, Van Cruchten S.

Pharm Res. 2017 Apr;34(4):750-764. doi: 10.1007/s11095-017-2101-y. Epub 2017 Jan 17.

PMID:
28097507
11.

Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.

Snoeys J, Beumont M, Monshouwer M, Ouwerkerk-Mahadevan S.

Clin Pharmacokinet. 2017 Jul;56(7):781-792. doi: 10.1007/s40262-016-0476-2.

PMID:
27896690
12.

In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.

Mamidi RNVS, Dallas S, Sensenhauser C, Lim HK, Scheers E, Verboven P, Cuyckens F, Leclercq L, Evans DC, Kelley MF, Johnson MD, Snoeys J.

Br J Clin Pharmacol. 2017 May;83(5):1082-1096. doi: 10.1111/bcp.13186. Epub 2016 Dec 20.

13.

Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.

Dragovic S, Vermeulen NP, Gerets HH, Hewitt PG, Ingelman-Sundberg M, Park BK, Juhila S, Snoeys J, Weaver RJ.

Arch Toxicol. 2016 Dec;90(12):2979-3003. Epub 2016 Sep 22. Review.

14.

In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity.

Monbaliu J, Gonzalez M, Bernard A, Jiao J, Sensenhauser C, Snoeys J, Stieltjes H, Wynant I, Smit JW, Chien C.

Drug Metab Dispos. 2016 Oct;44(10):1682-91. doi: 10.1124/dmd.116.070672. Epub 2016 Aug 8.

15.

Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.

de Zwart L, Snoeys J, De Jong J, Sukbuntherng J, Mannaert E, Monshouwer M.

Clin Pharmacol Ther. 2016 Nov;100(5):548-557. doi: 10.1002/cpt.419. Epub 2016 Aug 27.

PMID:
27367453
16.

Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.

T'jollyn H, Snoeys J, Van Bocxlaer J, De Bock L, Annaert P, Van Peer A, Allegaert K, Mannens G, Vermeulen A, Boussery K.

Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):537-543. doi: 10.1007/s13318-016-0355-0.

PMID:
27317395
17.

Discovery of 1-((2R,4aR,6R,7R,7aR)-2-Isopropoxy-2-oxidodihydro-4H,6H-spiro[furo[3,2-d][1,3,2]dioxaphosphinine-7,2'-oxetan]-6-yl)pyrimidine-2,4(1H,3H)-dione (JNJ-54257099), a 3'-5'-Cyclic Phosphate Ester Prodrug of 2'-Deoxy-2'-Spirooxetane Uridine Triphosphate Useful for HCV Inhibition.

Jonckers TH, Tahri A, Vijgen L, Berke JM, Lachau-Durand S, Stoops B, Snoeys J, Leclercq L, Tambuyzer L, Lin TI, Simmen K, Raboisson P.

J Med Chem. 2016 Jun 23;59(12):5790-8. doi: 10.1021/acs.jmedchem.6b00382. Epub 2016 Jun 3.

PMID:
27181575
18.

Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease.

Bell CC, Hendriks DF, Moro SM, Ellis E, Walsh J, Renblom A, Fredriksson Puigvert L, Dankers AC, Jacobs F, Snoeys J, Sison-Young RL, Jenkins RE, Nordling Å, Mkrtchian S, Park BK, Kitteringham NR, Goldring CE, Lauschke VM, Ingelman-Sundberg M.

Sci Rep. 2016 May 4;6:25187. doi: 10.1038/srep25187.

19.

In Vitro Model for Hepatotoxicity Studies Based on Primary Human Hepatocyte Cultivation in a Perfused 3D Bioreactor System.

Knöspel F, Jacobs F, Freyer N, Damm G, De Bondt A, van den Wyngaert I, Snoeys J, Monshouwer M, Richter M, Strahl N, Seehofer D, Zeilinger K.

Int J Mol Sci. 2016 Apr 16;17(4):584. doi: 10.3390/ijms17040584.

20.

The Effect of Food on the Intraluminal Behavior of Abiraterone Acetate in Man.

Geboers S, Stappaerts J, Mols R, Snoeys J, Tack J, Annaert P, Augustijns P.

J Pharm Sci. 2016 Sep;105(9):2974-2981. doi: 10.1016/j.xphs.2016.03.008. Epub 2016 Apr 7.

PMID:
27061460
21.

Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.

de Vries R, Smit JW, Hellemans P, Jiao J, Murphy J, Skee D, Snoeys J, Sukbuntherng J, Vliegen M, de Zwart L, Mannaert E, de Jong J.

Br J Clin Pharmacol. 2016 Feb;81(2):235-45. doi: 10.1111/bcp.12787. Epub 2016 Jan 15.

22.

A physiologically based pharmacokinetic modeling approach to predict drug-drug interactions between domperidone and inhibitors of CYP3A4.

Templeton I, Ravenstijn P, Sensenhauser C, Snoeys J.

Biopharm Drug Dispos. 2016 Jan;37(1):15-27. doi: 10.1002/bdd.1992.

PMID:
26356245
23.

Drug-Drug Interactions with the NS3/4A Protease Inhibitor Simeprevir.

Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, Beumont-Mauviel M, Simion A.

Clin Pharmacokinet. 2016 Feb;55(2):197-208. doi: 10.1007/s40262-015-0314-y. Review.

24.

Mechanistic understanding of the nonlinear pharmacokinetics and intersubject variability of simeprevir: A PBPK-guided drug development approach.

Snoeys J, Beumont M, Monshouwer M, Ouwerkerk-Mahadevan S.

Clin Pharmacol Ther. 2016 Feb;99(2):224-34. doi: 10.1002/cpt.206. Epub 2015 Nov 10.

PMID:
26259716
25.

Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.

T'jollyn H, Snoeys J, Vermeulen A, Michelet R, Cuyckens F, Mannens G, Van Peer A, Annaert P, Allegaert K, Van Bocxlaer J, Boussery K.

AAPS J. 2015 Nov;17(6):1376-87. doi: 10.1208/s12248-015-9803-z. Epub 2015 Jul 25.

26.

Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.

de Jong J, Skee D, Murphy J, Sukbuntherng J, Hellemans P, Smit J, de Vries R, Jiao JJ, Snoeys J, Mannaert E.

Pharmacol Res Perspect. 2015 Aug;3(4):e00156. doi: 10.1002/prp2.156. Epub 2015 Jun 24.

27.

The utility of HepG2 cells to identify direct mitochondrial dysfunction in the absence of cell death.

Kamalian L, Chadwick AE, Bayliss M, French NS, Monshouwer M, Snoeys J, Park BK.

Toxicol In Vitro. 2015 Jun;29(4):732-40. doi: 10.1016/j.tiv.2015.02.011. Epub 2015 Mar 5.

28.

Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.

Jones HM, Chen Y, Gibson C, Heimbach T, Parrott N, Peters SA, Snoeys J, Upreti VV, Zheng M, Hall SD.

Clin Pharmacol Ther. 2015 Mar;97(3):247-62. doi: 10.1002/cpt.37. Epub 2015 Jan 9. Review.

PMID:
25670209
29.

Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies.

Stappaerts J, Geboers S, Snoeys J, Brouwers J, Tack J, Annaert P, Augustijns P.

Eur J Pharm Biopharm. 2015 Feb;90:1-7. doi: 10.1016/j.ejpb.2015.01.001. Epub 2015 Jan 12.

PMID:
25592324
30.

Physiology-based IVIVE predictions of tramadol from in vitro metabolism data.

T'jollyn H, Snoeys J, Colin P, Van Bocxlaer J, Annaert P, Cuyckens F, Vermeulen A, Van Peer A, Allegaert K, Mannens G, Boussery K.

Pharm Res. 2015 Jan;32(1):260-74. doi: 10.1007/s11095-014-1460-x. Epub 2014 Jul 22.

PMID:
25048637
31.

Confocal imaging with a fluorescent bile acid analogue closely mimicking hepatic taurocholate disposition.

De Bruyn T, Sempels W, Snoeys J, Holmstock N, Chatterjee S, Stieger B, Augustijns P, Hofkens J, Mizuno H, Annaert P.

J Pharm Sci. 2014 Jun;103(6):1872-81. doi: 10.1002/jps.23933. Epub 2014 Mar 20.

PMID:
24652646
32.

The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement.

Poggesi I, Snoeys J, Van Peer A.

Expert Opin Drug Metab Toxicol. 2014 May;10(5):631-5. doi: 10.1517/17425255.2014.888058. Epub 2014 Feb 11.

PMID:
24517185
33.

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.

Vieira ML, Kirby B, Ragueneau-Majlessi I, Galetin A, Chien JY, Einolf HJ, Fahmi OA, Fischer V, Fretland A, Grime K, Hall SD, Higgs R, Plowchalk D, Riley R, Seibert E, Skordos K, Snoeys J, Venkatakrishnan K, Waterhouse T, Obach RS, Berglund EG, Zhang L, Zhao P, Reynolds KS, Huang SM.

Clin Pharmacol Ther. 2014 Feb;95(2):189-98. doi: 10.1038/clpt.2013.187. Epub 2013 Sep 18.

PMID:
24048277
34.

Pharmacokinetic interaction between telaprevir and methadone.

van Heeswijk R, Verboven P, Vandevoorde A, Vinck P, Snoeys J, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Witek J, Garg V.

Antimicrob Agents Chemother. 2013 May;57(5):2304-9. doi: 10.1128/AAC.02262-12. Epub 2013 Mar 11.

35.

Evaluation of miR-122 and other biomarkers in distinct acute liver injury in rats.

Starckx S, Batheja A, Verheyen GR, Jonghe SD, Steemans K, Dijck BV, Singer M, Bogdan N, Snoeys J, Vinken P, Sasaki JC, Gompel JV, Guzzie-Peck P, Lampo A, Lammens L.

Toxicol Pathol. 2013 Jul;41(5):795-804. doi: 10.1177/0192623312464436. Epub 2012 Nov 9.

PMID:
23143187
36.
37.

Hepatocyte-specific ABCA1 transfer increases HDL cholesterol but impairs HDL function and accelerates atherosclerosis.

Feng Y, Lievens J, Jacobs F, Hoekstra M, Van Craeyveld E, Gordts SC, Snoeys J, De Geest B.

Cardiovasc Res. 2010 Nov 1;88(2):376-85. doi: 10.1093/cvr/cvq204. Epub 2010 Jun 18.

PMID:
20562425
38.

The relative atherogenicity of VLDL and LDL is dependent on the topographic site.

Van Craeyveld E, Jacobs F, Feng Y, Thomassen LC, Martens JA, Lievens J, Snoeys J, De Geest B.

J Lipid Res. 2010 Jun;51(6):1478-85. doi: 10.1194/jlr.M003509. Epub 2010 Jan 19.

39.

Species-specific interaction of HIV protease inhibitors with accumulation of cholyl-glycylamido-fluorescein (CGamF) in sandwich-cultured hepatocytes.

Ye ZW, Van Pelt J, Camus S, Snoeys J, Augustijns P, Annaert P.

J Pharm Sci. 2010 Jun;99(6):2886-98. doi: 10.1002/jps.22018.

PMID:
20014428
40.

The impact of antigen expression in antigen-presenting cells on humoral immune responses against the transgene product.

Feng Y, Jacobs F, Van Craeyveld E, Lievens J, Snoeys J, Van Linthout S, De Geest B.

Gene Ther. 2010 Feb;17(2):288-93. doi: 10.1038/gt.2009.125. Epub 2009 Sep 17.

PMID:
19759564
41.

Species differences in hepatocyte-directed gene transfer: implications for clinical translation.

Jacobs F, Feng Y, Van Craeyveld E, Lievens J, Snoeys J, De Geest B.

Curr Gene Ther. 2009 Apr;9(2):83-90. Review.

PMID:
19355866
42.

Apolipoprotein A-I and lecithin:cholesterol acyltransferase transfer induce cholesterol unloading in complex atherosclerotic lesions.

Van Craeyveld E, Lievens J, Jacobs F, Feng Y, Snoeys J, De Geest B.

Gene Ther. 2009 Jun;16(6):757-65. doi: 10.1038/gt.2009.8. Epub 2009 Feb 26.

PMID:
19242527
43.

Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent.

Feng Y, Van Craeyveld E, Jacobs F, Lievens J, Snoeys J, De Geest B.

J Mol Med (Berl). 2009 Mar;87(3):287-97. doi: 10.1007/s00109-008-0427-y. Epub 2008 Dec 10.

PMID:
19066833
44.

Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling.

Hay DC, Fletcher J, Payne C, Terrace JD, Gallagher RC, Snoeys J, Black JR, Wojtacha D, Samuel K, Hannoun Z, Pryde A, Filippi C, Currie IS, Forbes SJ, Ross JA, Newsome PN, Iredale JP.

Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12301-6. doi: 10.1073/pnas.0806522105. Epub 2008 Aug 21.

45.

Adenoviral low density lipoprotein receptor attenuates progression of atherosclerosis and decreases tissue cholesterol levels in a murine model of familial hypercholesterolemia.

Jacobs F, Van Craeyveld E, Feng Y, Snoeys J, De Geest B.

Atherosclerosis. 2008 Dec;201(2):289-97. doi: 10.1016/j.atherosclerosis.2008.02.023. Epub 2008 Mar 4.

PMID:
18378244
46.

Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer.

Jacobs F, Snoeys J, Feng Y, Van Craeyveld E, Lievens J, Armentano D, Cheng SH, De Geest B.

Gene Ther. 2008 Apr;15(8):594-603. doi: 10.1038/sj.gt.3303096. Epub 2008 Feb 21.

PMID:
18288213
47.

Human ApoA-I transfer attenuates transplant arteriosclerosis via enhanced incorporation of bone marrow-derived endothelial progenitor cells.

Feng Y, Jacobs F, Van Craeyveld E, Brunaud C, Snoeys J, Tjwa M, Van Linthout S, De Geest B.

Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):278-83. Epub 2007 Dec 6.

PMID:
18063807
48.

Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae.

Snoeys J, Lievens J, Wisse E, Jacobs F, Duimel H, Collen D, Frederik P, De Geest B.

Gene Ther. 2007 Apr;14(7):604-12. Epub 2007 Jan 18.

PMID:
17235290
49.

Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in mice does not affect adipogenesis or adipose tissue development.

Demeulemeester D, Scroyen I, Voros G, Snoeys J, De Geest B, Collen D, Lijnen HR.

Thromb Haemost. 2006 Jun;95(6):1019-24.

PMID:
16732382
50.

Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone.

De Geest B, Snoeys J, Van Linthout S, Lievens J, Collen D.

Hum Gene Ther. 2005 Dec;16(12):1439-51.

PMID:
16390275

Supplemental Content

Loading ...
Support Center